[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338412-105":59,"doc-detail-338412-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","trastuzumab-deruxtecan-in-advanced-solid-tumors-with-human-epidermal-growth-factor-receptor-2-amplification-identified-by-plasma-cell-free-dna-testing-a-multicenter-single-arm-phase-ii-basket-trial","Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing - A Multicenter Single-Arm Phase II Basket Trial","","HERALD/EPOC1806 assessed trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)–amplified progressive stage solid tumors identified by cell-free DNA (cfDNA) testing. Patients with HER2 amplification detected by next-generation sequencing of cfDNA received T-DXd 5.4 mg/kg every 3 weeks until progression or unacceptable toxicity. Among 4,734 cfDNA-tested patients, 252 had HER2 amplification and 62 were enrolled across 16 cancer types, achieving an investigator-assessed confirmed overall response rate of 56.5% and durable benefit. Median progression-free survival was 7.0 months and median response duration was 8.8 months, with mostly mild-to-moderate adverse events; interstitial lung disease occurred in 26% of patients.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/trastuzumab-deruxtecan-in-advanced-solid-tumors-with-human-epidermal-growth-factor-receptor-2-amplification-identified-by-plasma-cell-free-dna-testing-a-multicenter-single-arm-phase-ii-basket-trial/338412/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/trastuzumab-deruxtecan-in-advanced-solid-tumors-with-human-epidermal-growth-factor-receptor-2-amplification-identified-by-plasma-cell-free-dna-testing-a-multicenter-single-arm-phase-ii-basket-trial/338412.png","ImageObject",300,407,{"name":92,"@type":93},"Eden","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary goal of the HERALD/EPOC1806 trial?","Question",{"text":113,"@type":114},"To evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-amplified solid tumors identified by cfDNA testing.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were patients selected for treatment in this study?",{"text":118,"@type":114},"Patients had advanced solid tumors with HER2 amplification identified via next-generation sequencing of plasma cfDNA, without requiring immunohistochemical HER2 testing.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes and safety findings were reported for T-DXd?",{"text":122,"@type":114},"The confirmed overall response rate was 56.5%, with median progression-free survival of 7.0 months and median response duration of 8.8 months; interstitial lung disease occurred in 26% of patients, mostly mild to moderate.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338412,1790185582,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Original Reports | Translational Oncology  \nTrastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Ampliﬁcation Identiﬁed by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial  \nMasataka Yagisawa, MD, PhD1,2 ; Hiroya Taniguchi, MD, PhD1,3 ; Taroh Satoh, MD, PhD4 ; Shigenori Kadowaki, MD, PhD3 ; Yu Sunakawa, MD, PhD5 ; Tomohiro Nishina, MD, PhD6; Yoshito Komatsu, MD, PhD7 ; Taito Esaki, MD, PhD8; Daisuke Sakai, MD4 ; Ayako Doi, MD5 ; Takeshi Kajiwara, MD, PhD6 ; Hiromi Ono, BVM9; Masatoshi Asano, MPharm9; Nami Hirano, BMLS9;  \nJustin Odegaard, MD, PhD10; Satoshi Fujii, MD, PhD11 ; Shogo Nomura, PhD12 ; Hideaki Bando, MD, PhD1,13 ; Akihiro Sato, MD, PhD9; Takayuki Yoshino, MD, PhD1 ; and Yoshiaki Nakamura, MD, PhD1,13   \nDOI [https://doi.org/10.1200/JCO.23.02626](https://doi.org/10.1200/JCO.23.02626)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)–ampliﬁed progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. |\n| PATIENTS AND METHODS | Patients exhibited advanced solid tumors with HER2 ampliﬁcation that wasidentiﬁed via next-generation sequencing of cfDNA testing, without the requirement for immunohistochemical HER2 testing. The studied group was administered T-DXd at 5.4 mg/kg once every 3 weeks until onset of disease progression or intolerable toxicity. |\n| RESULTS | Overall, 4,734 patients underwent cfDNA testing from December 2019 to January 2022, and 252 demonstrated HER2 ampliﬁcation. Finally, the study included 62 patients with 16 cancer types with a median baseline plasma HER2 copy number (CN) of 8.55 (range, 2.4-73.9) . Conﬁrmed overall response rate (ORR) by investigator assessment was 56.5%(95% CI, 43.3 to 69.0), thus showing a value beyond the 5%threshold. Responses were evaluated for 13 cancer types, including KRAS-mutant colorectal (1/3), PIK3CA-mutant endometrial (5/6), and tissue HER2-negative gastric (1/2) cancers. Plasma HER2 CN above versus below the baseline median value did not differ for impact response; however, clearance of HER2 ampliﬁcation in cfDNA on cycle 2 day 1 had higher response values compared with persistence. Median progression-free survival and response duration were 7.0 (95% CI, 4.9 to 9.7) and 8.8 (95% CI, 5.8 to 11.2) months, respectively, with the majority of complications being mild to moderate. Interstitial lung diseases were identiﬁed in 16 (26%) patients, including 14 patients with grade 1 disease, one patient with grade 2 disease, and one patient with grade 3 disease. |\n| CONCLUSION | T-DXd treatment demonstrated high ORR with durable response in patients with advanced HER2-ampliﬁed solid tumors determined with cfDNA testing. |\n\nACCOMPANYING CONTENT  \n Appendix  \n Data Sharing Statement  \n Data Supplement  Protocol  \nAccepted May 10, 2024 Published August 1, 2024  \nJ Clin Oncol 42:3817-3825 © 2024 by American Society of Clinical Oncology  \nView Online Article  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nHuman epidermal growth factor receptor 2 (HER2) is atransmembrane tyrosine kinase receptor, the protein structure of which is encoded by the ERBB2 (HER2) gene (chromosome 17q12) . Ampliﬁcation of the HER2 gene is associated with cell proliferation, migration, and differentiation processes in 15%-20% of breast and gastric cancers. HER2-targeted drugs representing HER2 antibodies include trastuzumab and pertuzumab, and tyrosine kinase inhibitors  \nsuch as lapatinib, neratinib, and tucatinib being a part of common therapeutic regimens.1-3 Moreover, HER2 ampliﬁ cation can be a therapeutic target as observed in 2%-3% of other solid tumors.4-6 However, HER2-targeted therapies for HER2-ampliﬁed solid tumors have yet tobe standardized for these patients.  \nCell-free DNA (cfDNA) is routinely us","cbCaipnyfdX0NwOx","https://ap.wps.com/l/cbCaipnyfdX0NwOx","pdf",1372697,14,"English","# Abstract\n## Purpose\n## Patients and Methods\n## Results\n## Conclusion\n# Introduction\n## HER2 biology and clinical relevance\n## cfDNA as a biomarker\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What was the primary goal of the HERALD/EPOC1806 trial?\",\"answer\":\"To evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-amplified solid tumors identified by cfDNA testing.\"},{\"question\":\"How were patients selected for treatment in this study?\",\"answer\":\"Patients had advanced solid tumors with HER2 amplification identified via next-generation sequencing of plasma cfDNA, without requiring immunohistochemical HER2 testing.\"},{\"question\":\"What outcomes and safety findings were reported for T-DXd?\",\"answer\":\"The confirmed overall response rate was 56.5%, with median progression-free survival of 7.0 months and median response duration of 8.8 months; interstitial lung disease occurred in 26% of patients, mostly mild to moderate.\"}]","Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing - A Multicenter Single-Arm Phase II Basket Trial | PDF",1790023548,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d99800cb50fe66b7c7c904f7f7a29895.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bec0d093a1688b611edcd5c40867b455.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0681fd8cf325286e388172c28d361492.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64428ba369c7edf18d79a2bbd1c421ce.webp",980,1311]